138 terminated. 138 Phase 3, 16 Phase 2.
By phase and status
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Trials (filtered) newest first · largest first
All 138 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)
FYB206, Keytruda - Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Terminated | 25 | 2024-10-03 | 2025-06-26 |
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
BAT3306, EU-Keytruda®, US-Keytruda® - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | 162 | 2024-07-19 | 2025-12-02 |
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy
Atezolizumab, Tiragolumab, Placebo - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Terminated | 56 | 2024-03-21 | 2026-06-10 |
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)
Pembrolizumab/Vibostolimab, Carboplatin, Cisplatin - Metastatic Non-Small Cell Lung Cancer | Phase 3 | Terminated | 739 | 2022-03-24 | 2026-09-11 |
A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer
Canakinumab, Placebo - Lung Cancer | Phase 3 | Terminated | 350 | 2022-02-03 | 2023-02-13 |
Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer
Thoracic radiotherapy, Chemo-immunotherapy - Small-cell Lung Cancer | Phase 3 | Terminated | 239 | 2022-01-11 | 2026-01-28 |
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
Cosibelimab, Cisplatin, Carboplatin - Metastatic Non-squamous Non Small Cell Lung Cancer | Phase 3 | Terminated | 25 | 2021-12-08 | 2025-04-02 |
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
Capmatinib, Osimertinib, Pemetrexed - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | 6 | 2021-09-22 | 2024-03-05 |
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma | Phase 3 | Terminated | 19 | 2021-08-05 | 2026-05-20 |
Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Tislelizumab, Docetaxel, Sitravatinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Terminated | 377 | 2021-07-27 | 2025-06-29 |
A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
Tislelizumab, Durvalumab, Ociperlimab - Non Small Cell Lung Cancer | Phase 3 | Terminated | 63 | 2021-06-17 | 2024-10-31 |
A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
Tislelizumab, Ociperlimab, Pembrolizumab - Non-small Cell Lung Cancer, NSCLC | Phase 3 | Terminated | 669 | 2021-05-24 | 2026-05-12 |
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Pembrolizumab/Vibostolimab, Pembrolizumab - Lung Neoplasms, Non-Small-Cell Lung Carcinoma | Phase 3 | Terminated | 1264 | 2021-04-07 | 2026-09-17 |
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
Capmatinib, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | 22 | 2020-09-25 | 2025-05-16 |
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial
Sevoflurane, Propofol, Lidocaine IV - Colonic Cancer, Rectal Cancer | Phase 3 | Terminated | 254 | 2020-07-31 | 2025-03-14 |
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Pralsetinib, Carboplatin, Cisplatin - RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm | Phase 3 | Terminated | 223 | 2020-07-24 | 2026-03-05 |
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
Carboplatin, Cisplatin, Decortication - Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma | Phase 3 | Terminated | 16 | 2020-01-29 | 2026-07-13 |
SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer
SCT-I10, Docetaxel, Placebo - Squamous-cell Non-Small-cell Lung Cancer | Phase 3 | Terminated | 188 | 2019-10-22 | 2024-02-09 |
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo - Non-Small Cell Lung Cancer | Phase 3 | Terminated | 448 | 2019-06-25 | 2025-12-11 |
A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer
Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | 1 | 2019-05-22 | 2020-07-15 |
Showing 20 of 138. Sign in to see all of them.
Narrower conditions
Carcinoma, Non-Small-Cell Lung (105) · Lung Neoplasms (54) · Neoplasms (12) · Neoplasm Metastasis (10) · Small Cell Lung Carcinoma (9) · Adenocarcinoma of Lung (6) · Breast Neoplasms (5) · Carcinoma (5) · Adenocarcinoma, Bronchiolo-Alveolar (4) · Brain Neoplasms (4) · Carcinoma, Squamous Cell (4) · Head and Neck Neoplasms (4) · Prostatic Neoplasms (4) · Colonic Neoplasms (3) · Colorectal Neoplasms (3)
Broader conditions
Lung Diseases (135) · Neoplasms by Site (135) · Respiratory Tract Diseases (135) · Respiratory Tract Neoplasms (135) · Neoplasms (126) · Carcinoma, Bronchogenic (112) · Bronchial Neoplasms (111) · Lung Neoplasms (84) · Pathological Conditions, Signs and Symptoms (19) · Neoplasms by Histologic Type (18) · Neoplasms, Glandular and Epithelial (18) · Pathologic Processes (14) · Carcinoma (12) · Neoplastic Processes (10)
Interventions
Carboplatin (31) · Cisplatin (25) · Paclitaxel (22) · Docetaxel (21) · Pemetrexed (21) · Gemcitabine (14) · Erlotinib Hydrochloride (11) · pembrolizumab (10) · Radiotherapy (8) · Bevacizumab (5) · Drug Therapy (5) · Radiosurgery (5) · Vinorelbine (5) · paclitaxel poliglumex (5) · 130-nm albumin-bound paclitaxel (4)
Sponsors
Novartis Pharmaceuticals (7) · Alliance for Clinical Trials in Oncology (5) · CTI BioPharma (5) · Merck Sharp & Dohme LLC (4) · Pfizer (4) · BeiGene (3) · European Organisation for Research and Treatment of Cancer - EORTC (3) · Hoffmann-La Roche (3) · National Cancer Institute (NCI) (3) · Amgen (2) · Bayer (2) · Bioven Europe (2) · Clovis Oncology, Inc. (2) · Daiichi Sankyo (2) · Mario Negri Institute for Pharmacological Research (2)
Countries
United States (75) · Italy (37) · Germany (36) · France (35) · Spain (34) · Canada (32) · United Kingdom (31) · Poland (30) · South Korea (28) · China (26) · Hungary (25) · Netherlands (25) · Taiwan (25) · Belgium (24) · Russia (22)
Top investigators
Mary O'Brien, MD (2) · Akira Yokoyama, MD, PhD (1) · Alex Adjei (1) · Andrea Ardizzoni, M.D. (1) · Andrea De Censi (1) · Andreas Rimner, MD (1) · Ara Vaporciyan, MD, BS (1)
Results publications
PMID 38468440, PMID 41332393, PMID 34870327, PMID 17084621, PMID 17312332, PMID 17406356, PMID 17936405, PMID 18520802, PMID 18594318, PMID 20212250, PMID 21802939, PMID 21982342, PMID 22440336, PMID 22795435, PMID 23643177, PMID 24419239, PMID 24888810, PMID 25164908, PMID 25378648, PMID 25395283, PMID 26153496, PMID 26169611, PMID 26727163, PMID 27264267, PMID 27923550, PMID 28489511, PMID 28891835, PMID 28923084, PMID 29169877, PMID 29238824, PMID 29290251, PMID 30291834, PMID 30472259, PMID 30702971, PMID 30821824, PMID 31070709, PMID 31509028, PMID 31618297, PMID 32543258, PMID 33668061, PMID 33948123, PMID 34753703, PMID 35342321, PMID 35833116, PMID 36920652, PMID 37419867, PMID 37704166, PMID 37788412, PMID 38039427, PMID 38354535
NIH funding
2023 (6), 2018 (3), 2005 (2), 2014 (2), 2015 (2), 2016 (2), 2017 (2), U10CA180868 (2), 2004 (1), 2019 (1), K23CA115908 (1), U10CA021115 (1), U10CA021661 (1), U10CA025224 (1), U10CA032102 (1)